tiprankstipranks
Advertisement
Advertisement

CTNM Stock Latest News

Contineum price target raised to $16 from $14 at Morgan Stanley
The FlyContineum price target raised to $16 from $14 at Morgan Stanley
7d ago
CTNM
Contineum Therapeutics Reports Positive Phase 1b Chronic Pain Data
PremiumCompany Announcements
Contineum Therapeutics Reports Positive Phase 1b Chronic Pain Data
20d ago
8K
CTNM
Contineum reports positive topline data from exploratory PIPE-791 Phase 1b
PremiumThe Fly
Contineum reports positive topline data from exploratory PIPE-791 Phase 1b
20d ago
CTNM
Contineum price target raised to $20 from $14 at Baird
PremiumThe Fly
Contineum price target raised to $20 from $14 at Baird
3M ago
CTNM
Contineum Therapeutics Expands ATM Facility, Highlights Pipeline Progress
PremiumCompany Announcements
Contineum Therapeutics Expands ATM Facility, Highlights Pipeline Progress
3M ago
8K
CTNM
Contineum reports Q4 EPS (49c), consensus (39c)
PremiumThe FlyContineum reports Q4 EPS (49c), consensus (39c)
3M ago
CTNM
Is CTNM a Buy, Before Earnings?
Premium
Pre-Earnings
Is CTNM a Buy, Before Earnings?
3M ago
CTNM
Contineum Therapeutics Adopts 2026 Employment Inducement Equity Plan
Premium
Company Announcements
Contineum Therapeutics Adopts 2026 Employment Inducement Equity Plan
4M ago
8K
CTNM
Contineum downgraded to Equal Weight from Overweight at Morgan Stanley
PremiumThe Fly
Contineum downgraded to Equal Weight from Overweight at Morgan Stanley
4M ago
CTNM
Contineum 7.4M share Spot Secondary priced at $12.25
PremiumThe Fly
Contineum 7.4M share Spot Secondary priced at $12.25
5M ago
CTNM
Contineum Therapeutics Submits Phase 2 Trial for PIPE-791
PremiumCompany Announcements
Contineum Therapeutics Submits Phase 2 Trial for PIPE-791
5M ago
8K
CTNM
Contineum offers to sell $75M in common stock
PremiumThe Fly
Contineum offers to sell $75M in common stock
5M ago
CTNM
Contineum price target lowered to $14 from $16 at Baird
PremiumThe FlyContineum price target lowered to $14 from $16 at Baird
6M ago
CTNM
Contineum price target lowered to $22 from $25 at RBC Capital
Premium
The Fly
Contineum price target lowered to $22 from $25 at RBC Capital
6M ago
CTNM
Contineum Therapeutics: Undervalued Potential in IPF with PIPE-791 Amidst PIPE-307 Setback
Premium
Ratings
Contineum Therapeutics: Undervalued Potential in IPF with PIPE-791 Amidst PIPE-307 Setback
6M ago
CTNM
Positive Outlook on Contineum Therapeutics Despite Setbacks, Driven by PIPE-791’s Potential in IPF
PremiumRatings
Positive Outlook on Contineum Therapeutics Despite Setbacks, Driven by PIPE-791’s Potential in IPF
6M ago
CTNM
Closing Bell Movers: Elastic down 12% despite beat and raise
PremiumThe Fly
Closing Bell Movers: Elastic down 12% despite beat and raise
6M ago
MU
GAP
Optimistic Buy Rating for Contineum Therapeutics Amid Promising PIPE-791 Developments
PremiumRatings
Optimistic Buy Rating for Contineum Therapeutics Amid Promising PIPE-791 Developments
6M ago
CTNM
Contineum Therapeutics Reports Phase 2 Trial Results
PremiumCompany Announcements
Contineum Therapeutics Reports Phase 2 Trial Results
6M ago
8K
CTNM
Contineum Therapeutics Inc trading resumes
PremiumThe FlyContineum Therapeutics Inc trading resumes
6M ago
CTNM
Contineum Phase 2 VISTA trial did not meet primary, secondary endpoints
Premium
The Fly
Contineum Phase 2 VISTA trial did not meet primary, secondary endpoints
6M ago
CTNM
Contineum Therapeutics Inc trading halted, news pending
Premium
The Fly
Contineum Therapeutics Inc trading halted, news pending
6M ago
CTNM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >